MCGIRR DAVID W J 4

What Happened

• Director David W. J. McGirr reported derivative and award activity for Rhythm Pharmaceuticals (RYTM). On June 23, 2026 he recorded the exercise/conversion of 4,712 derivative shares (reported as both an acquisition and a simultaneous disposition with $0 cash proceeds). On June 24, 2026 he was granted/received two restricted stock unit (RSU) awards totaling 6,015 RSUs (3,691 and 2,324 RSUs) reported at $0.00.

Key Details

• Transaction dates and reported prices:
  • 2026-06-23: Exercise/conversion (derivative) — 4,712 shares acquired (price N/A) and 4,712 shares disposed at $0.00 (reported as derivative).
  • 2026-06-24: Grants/awards — 3,691 RSUs and 2,324 RSUs acquired, both reported at $0.00.
• Total newly acquired RSUs: 6,015.
• Total derivative shares exercised/converted on file: 4,712.
• Footnotes:
  • Each RSU represents a contingent right to one share of common stock.
  • Some RSUs are described as fully vested with no expiration; other awards/options note vesting occurs upon the earlier of June 24, 2027 or the day before the issuer’s 2027 annual meeting, subject to continued service.
• Shares owned after these transactions are not specified in the provided filing excerpt.
• Filing date: 2026-06-25 for transactions through 2026-06-24 — filing appears timely (no late filing indicated).

Context

• The filing shows an option exercise/conversion and simultaneous disposition reported with $0 cash proceeds; the filing does not disclose the reason for the $0 disposition (e.g., whether shares were transferred, withheld for taxes, or otherwise). The RSUs are awards that convert to shares under the terms noted in the footnotes; some are already fully vested while others have future vesting conditions. These are acquisitive events (awards and option exercise/conversion) rather than open-market purchases or sales; they do not by themselves indicate the insider’s market view.